Mesoblast (ASX:MSB; Nasdaq:MESO) is developing and commercializing allogeneic cellular medicines to treat serious and life-threatening inflammatory diseases with significant, unmet medical needs. The Company's Phase 3 off-the-shelf mesenchymal lineage cell product candidates are: • RYONCIL™ (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD) • Remestemcel-L for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection • REVASCOR® for advanced chronic heart failure, and • MPC-06-ID for chronic low back pain due to degenerative disc disease. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast’s approach to product development is to ensure rigorous scientific investigations are performed with well-characterized cell populations in order to understand mechanisms of action for each potential indication. Extensive preclinical translational studies guide clinical trials that are structured to meet stringent safety and efficacy criteria set by international regulatory agencies. All trials are conducted under the continuing review of independent Data Safety Monitoring Boards comprised of independent medical experts and statisticians. Mesoblast has an extensive patent portfolio comprising approximately 1,000 patents and patent applications with protection extending through 2040 in all major markets. This intellectual property portfolio covers composition of matter, manufacturing, and therapeutic applications of mesenchymal lineage cells. The Company believes this patent estate provides strong global protection.
View Top Employees from Mesoblast LimitedWebsite | http://www.mesoblast.com |
Ticker | MESO |
Revenue | $32 million |
Funding | $434.3 million |
Employees | 92 (92 on RocketReach) |
Founded | 2004 |
Address | Level 38, 55 Collins St, Melbourne, Victoria 3000, AU |
Phone | +61 3 9639 6036 |
Fax | +61 3 9639 6030 |
Technologies |
JavaScript,
HTML,
Google Analytics
+32 more
(view full list)
|
Industry | Biotechnology, Biotechnology Research, Pharmaceuticals, Cell-based therapies, Healthcare, Science and Engineering, Drug Discovery, Cellular Medicines, Health Care, Mesenchymal Lineage Adult Stem Cells, Health Diagnostics, Regenerative Medicine |
Web Rank | 4 Million |
Keywords | Mesoblast, Mesbloast, Mesoblast Ltd., Pharmaceutical Companies New York, Mesoblast Intervertebral Disc |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 621 Companies, NAICS Code 62151 Companies, NAICS Code 6215 Companies, NAICS Code 32 Companies, NAICS Code 62 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies |
Looking for a particular Mesoblast Limited employee's phone or email?
The Mesoblast Limited annual revenue was $32 million in 2024.
Normand Davidzon is the Vice President, Engineering Technology of Mesoblast Limited.
92 people are employed at Mesoblast Limited.
Mesoblast Limited is based in Melbourne, Victoria.
The NAICS codes for Mesoblast Limited are [621, 62151, 6215, 32, 62, 3254, 325].
The SIC codes for Mesoblast Limited are [873, 87].